Technology Bundle ID
NCI-E-117-2016

T cell tuning molecules that modify the immune response to cancer cells

Applications
Therapeutics
Lead Inventors
Paul Love (NICHD)
Co-Inventors
J. Pinkhasov (NICHD)
Z. Li (NICHD)
Development Status
Discovery (Lead Identification)
ICs
NICHD

Researchers at NIH/NICHD have identified approximately 200 proteins as candidate molecules (leads) that “fine tune” T cell receptor (TCR) signaling. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks partners to collaborate on in vitro studies to validate these potential immunomodulators and to conduct in vivo studies in a murine cancer model to determine the effects of ligands (e.g. antibodies) to the proteins to determine their effect on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.

Commercial Applications

Agents that modify the immune response to cancer cells could be used in conjunction with other immunomodulators or therapeutic agents, such as vaccines

Request More Info

Licensing Contact: